Edition:
United States

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

1.08USD
21 Sep 2018
Change (% chg)

$-0.02 (-1.82%)
Prev Close
$1.10
Open
$1.11
Day's High
$1.11
Day's Low
$1.07
Volume
20,407
Avg. Vol
82,506
52-wk High
$13.43
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Sellas Life Sciences Files For Offering Of Up To $30 Mln
Wednesday, 23 May 2018 04:26pm EDT 

May 23 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING.  Full Article

Sellas Life Sciences Receives FDA Orphan Drug Designation For Galinpepimut-S For Treatment Of Multiple Myeloma
Wednesday, 9 May 2018 04:30pm EDT 

May 9 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM).  Full Article

Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer
Friday, 20 Apr 2018 08:45am EDT 

April 20 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER.SELLAS LIFE SCIENCES GROUP INC - INTERIM CHIEF FINANCIAL OFFICER ALEKSEY KRYLOV WILL REMAIN WITH SELLAS UNTIL JULY 15.SELLAS LIFE SCIENCES GROUP INC - MACK MOST RECENTLY SERVED AS A CONSULTING CFO, MOST RECENTLY WITH NICOX, SA.  Full Article

Sellas Life Sciences Group Files For Non-Timely 10 K With U.S. SEC
Monday, 2 Apr 2018 05:33pm EDT 

April 2 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP FILES FOR NON-TIMELY 10-K WITH U.S. SEC.  Full Article

Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin
Monday, 2 Apr 2018 08:40am EDT 

April 2 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS.CLINICALLY AND STATISTICALLY SIGNIFICANT EFFICACY IN TRIPLE NEGATIVE BREAST CANCER.CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCE WAS FOUND BETWEEN TWO ARMS IN COHORT OF PATIENTS​.‍ADDITION OF NEUVAX TO HERCEPTIN DID NOT RESULT IN ANY ADDITIONAL CARDIOTOXICITY COMPARED TO HERCEPTIN ALONE​.TOLERATED​.SPECIFIED INTERIM ANALYSIS SHOWED AN ADVERSE EVENT PROFILE WITH NO NOTABLE DIFFERENCES BETWEEN TREATMENT ARMS​.‍DSMB RECOMMENDED TO SEEK REGULATORY GUIDANCE BY FDA FOR FURTHER DEVELOPMENT OF COMBINATION OF NEUVAX + HERCEPTIN IN TNBC​.  Full Article

Sellas Life Sciences Announces $10.7 Mln Private Placement
Wednesday, 7 Mar 2018 09:00am EST 

March 7 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT.SELLAS LIFE SCIENCES - ‍FINANCING WILL SUPPORT ADVANCEMENT OF LATE-STAGE IMMUNO-ONCOLOGY PIPELINE​.  Full Article

Galena Biopharma posts Q3 loss $0.15/shr from continuing operations
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - ‍cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016​.  Full Article

Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​
Wednesday, 18 Oct 2017 05:44pm EDT 

Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing.Galena Biopharma Inc - ‍pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement​.Galena Biopharma Inc - ‍Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - ‍product swap agreement with Cardinal will be terminated as of effective date of agreement​.  Full Article

Galena Biopharma announces completion of enrollment in two NeuVax™ clinical trials in combination with Trastuzumab
Thursday, 28 Sep 2017 07:05am EDT 

Sept 28 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc announces completion of enrollment in two NeuVax™ (nelipepimut-s) clinical trials in combination with Trastuzumab.Galena Biopharma Inc - ‍look forward to interim results next year for phase 2b trial and primary endpoints for both trials in 2019​.Galena Biopharma Inc - ‍recommendation from dsmb was to continue her2 3+ trial unmodified.​.  Full Article

Galena Biopharma, unit of co and Biovascular, enters amendment of exclusive license agreement
Monday, 11 Sep 2017 07:32am EDT 

Sept 11 (Reuters) - Galena Biopharma Inc ::Galena Biopharma-‍on Sept 5, unit of co and Biovascular, entered amendment of exclusive license agreement between MPI and BVI dated December 20, 2013.Galena Biopharma - ‍pursuant to amendment parties agreed to resolve outstanding disputes over license agreement, to modify certain terms of agreement​.Galena Biopharma- ‍amendment to eliminate 3pct royalty rate on annual net sales of $50 million, 4pct royalty now applies to annual net sales of up to $100 million​.  Full Article

Sellas Life Sciences Group Inc News

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage:

» More SLS.OQ News

Earnings vs. Estimates

» More Financials